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Abstract Growth hormone receptor (GHR) signaling involves 
activation of the Janus Kinases (Jak) and of Stat proteins (signal 
transducers and activators of transcription). Growth hormone 
(GH) induces transcriptional activation of c-los gene and the c-sis 
inducible element (SIE) of its promoter was shown to bind the 
Stat proteins. Using cells co-transfected with GHR and Stat 3 
expression vectors, we directly demonstrate that GH induces 
tyrosine phosphorylation of Stat 3 and its binding to the SIE 
probe. We showed, using mutant forms of GHR, that only the 
cytoplasmic membrane proximal domain of the receptor, includ- 
ing a conserved proline rich region (box 1), is required for this 
effect. 
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1. Introduction 
response element (SRE) [1 1] and the c-sis-inducible lement 
(SIE) [12]. Previous tudies have shown that the SRE can medi- 
ate induction of c-Jos by GH [13]. It has also been shown that 
transcriptional complexes containing proteins antigenically re- 
lated to Stat 1 and Stat 3 were activated after GH stimulation, 
and were able to bind the SIE [14]. 
In this paper, we used CHO cells stably expressing GHR and 
COS-7 or 293 cells transiently cotransfected with GHR and 
Star 3 [15] expression vectors to demonstrate: (i) that Stat 3 is 
part of the GH-inducible complex which binds to a SIE related 
probe m67 [12], (ii) that GH induces tyrosine phosphorylation 
of Stat 3. Furthermore, using CHO cells expressing mutated 
forms of GHR, we demonstrate that the amino-terminal half 
of the GHR cytoplasmic domain is sufficient for Stat 3 activa- 
tion. In addition, the carboxy-terminal part of the receptor 
could play a role in the down regulation of the GH-induced 
transcriptional complex associated with the SIE probe. 
Growth hormone (GH) regulates the expression of many 
genes involved in growth, metabolism and cellular differentia- 
tion [1]. The first step of GH action is the binding of the 
hormone to its receptor (GHR) which belongs to the growth 
hormone/prolactin hematopoietic receptor superfamily [2]. Un- 
like receptor tyrosine kinases, receptors of this family do not 
have kinase domains and show only limited similarity in their 
cytoplasmic regions consisting in box 1 and box 2 motifs [3]. 
Binding of GH induces dimerisation of its receptor [4], activa- 
tion of the GHR associated kinase Jak 2 [5], and initiation of 
a cascade of protein tyrosine phosphorylations [6]. Jak 2 is also 
involved in the signaling pathway of several receptors of the 
family (review in [7]). Recently a direct coupling pathway was 
discovered between cytokine receptors and transcription [8]. 
The 'direct effector' mechanism proposed comprises a rapid 
activation by membrane receptorassociated tyrosine kinase(s) 
of Star transcription factors (signal transducers and activator 
of transcription) [9]. Thus, after dimerization, the Stat proteins 
are translocated to the nucleus where they bind to target nucleic 
acid sequences. In several cell lines, GH regulates the expres- 
sion of the proto-oncogene c-fos [10]. Two responsive lements 
have been described in the c-[i)s promoter egion: the serum 
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2. Experimental 
2.1. Construction of  expression p&smi& 
Plasmids containing the wild type GHR (GHRwt), the mutant 
GHR454 in pECE and the mutant GHR4~,,~ in pLM 1118 were described 
previously [16-18]. 
2.2. Cell culture and transJections 
Establishement of CHO stable clones, binding assays and cell culture 
conditions for CHO, COS-7 and 293 cells were performed as described 
[17,19]. COS-7 cells, plated in 100 mm dishes, were transiently trans- 
fected at 70% confluence by a DEAE-dextran-chloroquine procedure 
[18] with 5/tg of expression vector containing rabbit GHR cDNA and 
5/lg of expression vector containing Stat 3 or Star 1 cDNA (a generous 
gift from Pr. J. Darnell). 
2.3. Western blot analysis 
The human 293 clone expressing Jak 2 has been transfected as de- 
scribed [19] with 4/tg of GHRwt and 4 ,ug of Stat 3 expression vectors. 
Forty-eight hours after transfection, cells were stimulated 30 min with 
20 nM hGH. Cell lysates were immunoprecipitated with anti-Star 3 
(Santa Cruz Biotechnology) antibody and then subjected to Western 
blot analysis using anti-pTyr (UBI) or anti-Stat 3 antibody [19]. 
2.4. Eleetrophoretic mobility shift assay ( EMSA ) 
Confluent cells (COS-7 cells transiently transfected or CHO stable 
clones) were incubated with or without 20 nM hGH for various times. 
Cells were lyzed using hypotonic buffer (10 mM HEPES-KOH pH 7.9, 
1.5 mM MgClz, 10 mM KC1, 0.5 mM DTT, 1 mM Na3VO 4, 20 mM 
NaF, 1 mM phenylmethylsulfonylfluoride, 5 #g/ml aprotinin, 2/lg/ml 
leupeptin, 1//g/ml pepstatin) and nuclear extracts were prepared in high 
salt buffer (20 mM HEPES-KOH pH 7.9, 25% glycerol, 420 mM NaCL 
1.5 mM MgC1 z, 0.2 mM EDTA, 1 mM NaNO4, 20 mM NaF, antipro- 
teases). 
The sequence of the high affinity c-sis element (SIE) m67 (12) used 
in the gel shift assay is: top strand, 5'-GTCGACATTTCCCGTAAA- 
TCGTCGA-3" and bottom strand, 5'-TCGACGATTTACGGG-3'. 
The sequences of oligonucleotides (GAS, SRE, m34) used in competi- 
tion experiments are the ones described [12,13,20]. Double-stranded 
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probe was labeled using the Klenow fragment of E. coli DNA polym- 
erase I. Nuclear extracts (8 to 10 ¢tg) were incubated with 2 ~g of poly 
(dI-dC) in 10% glycerol, 0.5 mM EDTA, 0.5 mM DTT, 10 mM 
HEPES-KOH pH 7.9. 32P-labeled m67 probe (40,000 cpm, approxi- 
matively 0.5 ng) was added to the incubation for 20 min at room 
temperature. Fifty- and hundred-fold molar excess of unlabeled com- 
petitor oligonucleotide was added as indicated. For supershift experi- 
ments, incubations were carried out with 1/11 of anti-Stat 1 (Transduc- 
tion Laboratories), anti-Stat 3 or 1/~g of anti-pTyr antibodies 20 rain 
prior to the incubation with the labeled probe. The reaction was re- 
solved on a 5% acrylamide gel containing 0.25 x TBE buffer for 2 h at 
150 V. The gel was dried and exposed at -80°C to film (Kodak). 
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Fig. 1. GH induces a SIE-binding complex containing Stat 3. (A) CHO 
cells expressing GHRw~ were incubated for 30 min without (lane 1) or 
with 20 nM hGH (lanes 2-10). Electrophoretic mobility shift assays 
(EMSA) were performed using high affinity SIE labeled probe (m67) 
as described in section 2. For competition experiments, nuclear extracts 
were incubated with a 50-fold excess of unlabeled m67, GAS, mutated 
SIE sequence (m34) or SRE (lanes 3,5,7,9, respectively) or 100-fold 
excess (lanes 4,6,8,10) of the same probes. (B) Nuclear extracts from 
CHO cells expressing GHRwt treated (lanes 2-5) or not (lane 1) with 
20 nM hGH, were preincubated with anti-Stat 1 (lane 3), anti-Stat 3 
(lane 4) or anti-pTyr (lane 5) antibody. EMSA were performed using 
m67 labeled probe. 
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Fig. 2. Reconstitution of Star 3 activation in COS-7 cells. COS-7 cells 
were transiently co-transfected with GHR and Stat 3 (lanes 1-4) or Stat 
1 (lanes 5,6) expression vectors as described in section 2. Forty-eight 
hours after transfection, cells were treated (lanes 2,4,6) or not (lanes 
1,3,5) with 20 nM hGH for 30 min. The binding of nuclear extracts to 
labeled m67 probe was performed with (lane 3,4) or without a 100-fold 
excess of m67 unlabeled probe. 
3. Resu l ts  
In order to analyse the GH-inducible SIE binding complex, 
gel-mobility shift assays were performed. Nuclear extracts from 
CHO cells stably transfected with the rabbit GHRw, expression 
vector were incubated with a 32p-labeled high affinity SIE ol- 
igonucleotide (m67). As shown in Fig. I A, GH rapidly induced 
the appearance of a DNA-binding complex which was inhibited 
by an excess of unlabeled SIE competitor and to a lesser degree 
by an unlabeled GAS oligonucleotide derived from the Ly-6E 
gene. No competition was observed with a mutated SIE probe 
(m34) unable to bind c-sis inducible factors (SIF) or with a SRE 
probe, which was reported to bind proteins unrelated to the SIF 
complexes. Antibodies to Stat 1 and Stat 3 were used to deter- 
mine the composition of the GH regulated m67 binding com- 
plex (Fig. 1B). Preincubation of the nuclear extracts with anti- 
Stat 3 antibody resulted in a supershift while an incomplete 
supershift was observed with anti-Stat 1 antibody, a reduced 
signal was seen with anti-pTyr antibody. 
The presence of Stat 3 in the complex was further confirmed 
by experiments in which COS-7 cells were cotransfected with 
both GHR and Stat 3 cDNAs (Fig. 2). We clearly find under 
these conditions, a GH induced m67 binding complex, whereas 
only a constitutive complex was detected in co-transfection 
experiments with Stat 1 and GHR cDNAs. To investigate the 
ability of GH to induce tyrosine phosphorylation of Stat 3, 293 
cells were cotransfected with GHR and Stat 3 cDNAs, lm- 
munoprecipitations with anti-Stat 3 followed by Western blots 
with anti-pTyr or anti-Stat 3 antibodies demonstrated GH- 
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Fig. 3. GH induces tyrosine phosphorylation f Stat 3. A human 293 
clone expressing Jak 2 has been transfected with 4/lg Stat 3 eDNA 
alone (lanes 1,4) or with GHR cDNA (lanes 2,3,5,6). Forty eight hours 
after transfection, cells were incubated 30 min with 20 nM hGH. Cell 
lysates were immunoprecipitated with anti-Stat 3 antibody and then 
subjected to Western blot analysis using anti-pTyr or anti-Stat 3 anti- 
body. 
induced tyrosine phosphorylation of Stat 3 (Fig. 3). No signal 
was detected in untransfected 293 cells (data not shown). 
To identify the GHR domains involved in Stat 3 activation, 
different CHO cells expressing mutant forms of the GHR were 
used. As depicted in Fig. 3A, the mutant GHR454 lacks the 
C-terminal half of the cytoplasmic domain and the mutant 
GHR4p/A contains alanine substitutions of the four prolines in 
the conserved box 1 region. Scatchard analysis showed that the 
GH binding characteristics were equivalent (Kd values were 
respectively 0.45, 0.35 and 0.8 nM for CHO cells expressing 
GHRw~, GHR454 and GHR4p/A, while the number of sites ranged 
from 90,000 to 120,000 per cell). Western blots using ant i -GHR 
antibodies also confirmed the expected size of the mutant re- 
ceptors (data not shown). The m67 binding complexes formed 
with nuclear extracts from GHRw~ or from GHR454 expressing 
cells were similar in mobility and followed the same kinetics 
with a maximum binding at 15 30 rain (Fig. 3B). However, it 
should be noted that the intensity of the complex observed with 
nuclear extracts from cells expressing the GHR454 was much 
higher than that observed with cells expressing the wild type 
receptor. In contrast, no DNA-binding complex was observed 
in cells expressing the GHR4p/a mutant. Supershift studies with 
the mutant GH R4s4 suggested that the complex also contained 
essentially Stat 3 (Fig. 3C). 
4. Discuss ion  
Part of cytokine signaling to the cell nucleus operates 
through recruitement of Stat molecules in the activated recep- 
tor complex. These factors are subsequently phosphorylated on 
specific tyrosine residues precluding their dissociation from the 
receptor complex, their homo or heterodimerisation a d their 
migration to the nucleus where they bind specific sequences of 
cytokine responsive genes. The activation of Stat 1 and/or Stat 
3 molecules has been shown to be promoted by several igands: 
EGF, PDGF, LIF, IFN, GH, PRL [15,21-23], and this obser- 
vation raised the question of ligand induced transcriptional 
specificity. Specificity could be due to differential expression of 
the proteins (such as receptors and Stat family members) in 
different cells types or to the involvement of other molecules 
that could add post transcriptional modifications to the Stats 
molecules or associate with them to form an active transcrip- 
tional complex. In fact, GH appears to activate a protein anti- 
genically related to Stat 3 in liver (24), in 3T3 F442A preadi- 
pocytes [14] but not in IM-9 cells [25]. In this study, we directly 
show, using the cDNA encoding Stat 3, that the Stat 3 protein 
is activated by GH in COS-7 cells. In contrast, the involvement 
ofStat 1 in our experimental conditions is less clear: we observe 
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Fig. 4. Activation of m67-binding complex by GHR mutants. (A) Sche- 
matic representation f wild type and mutated forms of" GHR. Mutant 
forms of the receptor are shown below the wild type (wt); numbers 
indicate amino-acid (aa) residues. Residue 1 is the first aa of the mature 
protein. Boxes 1 and 2 are indicated as solid lines, the peptide signal 
sequence as a hatched rectangle, and the transmembrane domain as 
stippled rectangle. The four proline residues substituted in the box 1 
region (17) of the GHR4p/A mutant are indicated. (B) Kinetic character- 
istics of m67-binding complexes induced by GH in CHO cells express- 
ing wild type and mutant forms of GHR. CHO clones were stimulated 
or not for the indicated times with 20 nM hGH. Then the nuclear 
extracts were subjected to EMSA using m67 labeled probe. (C) The 
m67-binding complex induced by GH in CHO cells expressing GHR4~4 
contains Stat 3. Gel shift experiments were perl\~rmed with nuclear 
extracts from CHO cells expressing GHR4s 4 stimulated or not with 21) 
nM hGH for 30 min. For competition experiments, nuclear extracts 
were incubated with a 100-fold excess of m67 unlabeled probe. 
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in CHO cells a slight supershift of the m67 binding complex 
with anti-Stat 1 antibodies and a partial competition with the 
GAS probe, but no GH-inducible complex in COS-7 cells co- 
transfected with Stat 1 and GHR cDNAs. We thus hypothesize 
that Stat 1 can probably not form homodimers in response to 
GH stimulation but could participate in the formation of hetero- 
dimers with Stat 3. 
The analysis of GH signaling with different mutant forms of 
GHR allowed us to identify the region of the receptor required 
for the activation of Stat 3. The mutant GHR4P/A has been 
previously shown to be unable to activate Jak 2 [26] and unpub- 
lished personal observation). We show, in the present experi- 
ments, that this mutant is also unable to activate Stat 3, since 
no m67 binding complex was detected in cells expressing this 
modified form of the receptor. In contrast, the GHR454 mutant 
was fully able to induce GH dependent activation of Stat 3 as 
well as phosphorylation of Jak 2 and MAP kinase activation 
[17]. We conclude that the membrane proximal region of the 
GHR, containing the box 1, is essential and sufficient for Star 
3 activation and that this activation occurs likely in a Jak 2 
dependent pathway. This finding is in agreement with recent 
observations for GH [27] and GM-CSF [28] activation of Stat 
1 and Star 5 in Baf3 cells. It is also consistent with the 'direct 
effector' model in which the Star proteins are directly activated 
by membrane receptor tyrosine kinase complexes. A Stat 3- 
specifying YXXQ motif has been recently identified as a spe- 
cific target of the Stat 3 SH2 domain in the intracellular region 
of gpl30 or of the LIF receptor [29]. This sequence is not 
present in the GHR and we previously showed that in our 
system, the GHR454 mutant was not or very weakly tyrosine 
phosphorylated [17]. So, Stat 3 does not seem to bind to the 
GHR through a phosphorylated tyrosine. Specific sites for Star 
3 recruitement could be present in other proteins associated 
with the receptor complex. The Jak 2 kinase contains the 
YXXQ sequence and could perhaps erve as a docking mole- 
cule for Stat 3 in GHR signaling. 
The increased intensity of the m67-binding complex for the 
GHR454 mutant compared to the signal observed with the wild 
type receptor is puzzling. Both CHO clones have comparable 
binding characteristics and similar levels of Jak 2 activation. It
could be possible that GHR454 lacks a critical domain for the 
binding of molecules involved in negative regulation of Stat 3. 
We have previously shown that C-terminal tyrosines are prefer- 
entially phosphorylated after GH binding [17], one of these 
could be involved in the interaction with the SH2 domain of 
such regulatory proteins. A negative regulatory domain for Stat 
5 activation has also recently been reported in the carboxy- 
terminal region of the GM-CSF receptor [28]. 
Our results clearly show that the induction of Stat 3 binding 
to m67 by GH is mediated by the proximal region of the cyto- 
plasmic domain of GHR, but additional molecules (such as a 
phosphatase) might be associated to the C-terminal region of 
the receptor and could down regulate the binding activity of 
Stat 3 to SIE. This hypothesis currently under investigation. 
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